In premenopausal women with breast cancer who received no chemotherapy, goserelin was reported as more burdensome for physical symptoms than tamoxifen alone.
In plain wordsIn premenopausal women with breast cancer without chemotherapy, physical symptoms were more burdensome with goserelin than tamoxifen alone.
- Peptide
- Goserelin
- Outcome
- IncreasePhysical symptom burden without chemotherapy
- Study
n: not reported in source
- Comparator
- Tamoxifen alone
- Outcome group
- Adverse events · Whole body
- Studied dose
- Dose not stated · 2 yearsAs given in this study (human).
Source sentences
Goserelin was most burdensome and resulted in similar symptom levels as those of CMF, whereas the side effects of tamoxifen alone were milder.
4 context sentences(design, population, supporting numbers)
It was only among patients who did not receive chemotherapy that the endocrine treatment had differential effects.
To compare the effect of adjuvant endocrine therapies with and without chemotherapy on physical symptoms, anxiety, and depressive symptoms in premenopausal women with breast cancer in a randomized clinical trial (the Zoladex in Premenopausal Patients trial).
The patients were randomly assigned to goserelin, goserelin plus tamoxifen, tamoxifen alone, or no endocrine therapy.
The duration of the endocrine treatment was 2 years.